In an older adult, is it appropriate to prescribe Zopiclone 2.5 mg instead of the standard 5 mg dose?

Yes, 2.5 mg zopiclone is appropriate for elderly patients and may be preferable to 5 mg

In elderly patients, starting with zopiclone 2.5 mg (or 3.75 mg) is recommended over the standard 5 mg dose due to altered pharmacokinetics and increased risk of adverse events in this population.

Pharmacokinetic Rationale

Elderly patients demonstrate significantly altered zopiclone metabolism that necessitates dose reduction:

• Prolonged elimination half-life: Increases from 5.1 hours in young adults to 8.1 hours in patients over 74 years 1
• Increased bioavailability: Rises to 168% in the oldest subjects due to decreased metabolic clearance and altered volume of distribution 1
• Reduced hepatic metabolism: Metabolic ratios for both main metabolites (N-oxide and N-desmethyl derivatives) are decreased in elderly patients 1

These pharmacokinetic changes result in higher drug exposure and prolonged effects, increasing the risk of next-morning residual effects and adverse events.

Evidence-Based Dosing Recommendations

Starting Dose

The evidence consistently supports lower initial doses in elderly patients:

• 3.75 mg demonstrated efficacy: A geriatric study (mean age 81 years) found that 3.75 mg improved sleep quantity and quality with minimal side effects 2
• Dose-response relationship: While 7.5 mg showed optimal efficacy in elderly patients, the study noted that lower doses (3.75-5 mg) provided substantial benefit with better tolerability 2
• Formal recommendation: Based on pharmacokinetic data, a reduction from 7.5 mg to 3.75 mg is specifically recommended for patients over 70 years of age 1

Maximum Dose Considerations

If 2.5-3.75 mg proves insufficient, titration to 5 mg or 7.5 mg may be considered, but:

• 7.5 mg is generally considered the maximum appropriate dose for elderly patients 2
• Higher doses (10 mg) showed increased side effects without proportional benefit 2

Safety Profile in Elderly Patients

Adverse Events at Higher Doses

Recent high-quality evidence demonstrates significant risks with higher zopiclone doses in elderly populations:

Higher dose zopiclone (≥7.5 mg) in dementia patients was associated with 3:

• 67% increased fracture risk (HR 1.67,95% CI 1.13-2.46)
• 96% increased hip fracture risk (HR 1.96,95% CI 1.16-3.31)
• 33% increased fall risk (HR 1.33,95% CI 1.06-1.66)
• 88% increased ischemic stroke risk (HR 1.88,95% CI 1.14-3.10)

Critically, minimal or inconsistent excess risks were observed at ≤3.75 mg zopiclone equivalent daily 3, supporting the use of lower doses.

Cognitive and Psychomotor Effects

• Studies in geriatric patients showed no influence on psychomotor performance at doses of 3.75-7.5 mg 2
• However, in Alzheimer's patients, zopiclone 7.5 mg produced an 8-point reduction in digit-symbol coding test scores 4
• Next-morning residual effects are dose-dependent and more pronounced in elderly patients 5

Clinical Algorithm for Elderly Patients

Step 1: Initial Prescription

• Start with 2.5 mg or 3.75 mg zopiclone at bedtime
• Avoid taking with or immediately after high-fat meals (delays absorption by 1 hour)

Step 2: Assessment (after 3-7 days)

• Evaluate sleep improvement (sleep latency, total sleep time, nocturnal awakenings)
• Monitor for adverse effects: daytime sedation, falls, confusion, memory impairment

Step 3: Dose Adjustment if Needed

• If inadequate response and well-tolerated: increase to 5 mg
• If adequate response: continue current dose
• If adverse effects: reduce dose or discontinue

Step 4: Maximum Dose

• Do not exceed 7.5 mg in elderly patients
• Consider alternative approaches if 7.5 mg inadequate

Important Caveats and Pitfalls

Hepatic Impairment

If the elderly patient has liver insufficiency, further dose reduction is critical:

• Reduce initial dose to 3.75 mg or lower 1
• Bioavailability increases to 97% in hepatic impairment with prolonged half-life (8.4 hours) 1

Renal Impairment

• No dose adjustment necessary for renal impairment alone (less than 10% excreted unchanged in urine) 1
• However, elderly patients often have both age-related and renal-related pharmacokinetic changes

Duration of Treatment

• The American College of Physicians guideline emphasizes short-term use of nonbenzodiazepine hypnotics 6
• Behavioral therapy provides longer-term sustained benefit compared to pharmacotherapy 5
• Regular review of prescriptions is essential, particularly at higher doses 3

Comparison to Benzodiazepines

While zopiclone showed similar adverse event profiles to benzodiazepines for fractures and falls, it demonstrated lower mortality rates (HR 0.73,95% CI 0.64-0.83) 3, making it a reasonable choice when sedative-hypnotics are necessary.

Guideline Context

The 2009 JAGS guidelines emphasize that sedative-hypnotics in elderly patients should be started at the lowest available dose 5, which directly supports using 2.5 mg rather than 5 mg as the initial dose. The guidelines also note that older adults are at greater risk for adverse effects due to reduced drug clearance and increased sensitivity to peak drug effects 5.